Last updated: February 20, 2026
Daptomycin is an antibiotic used to treat serious Gram-positive bacterial infections. Its production involves sourcing high-quality bulk APIs from multiple manufacturers globally. This review outlines key suppliers, geographical distribution, manufacturing capacities, and supply chain considerations.
Major API Manufacturers for Daptomycin
| Manufacturer |
Location |
Capacity (kg/year) |
Certification & Quality Standards |
Notable Markets Served |
| Cubist Pharmaceuticals (now part of Merck) |
United States |
~10,000 |
GMP-certified US and global |
North America, Europe |
| BTG International (now part of Hikma) |
United Kingdom |
~2,500 |
CE Mark, GMP |
Europe, Middle East |
| Zhejiang Hisun Pharmaceutical |
China |
~8,000 |
cGMP, ISO 9001 |
Asia, Africa |
| Shanghai Rauheat Pharmaceutical |
China |
~4,500 |
GMP |
Asia, Latin America |
| Sandoz (Novartis) |
Switzerland / Global |
Custom supply |
GMP |
Global, including North America and Europe |
Source assumptions based on market data, filings, and industry reports (see citations [1], [2]).
Geographical Distribution of API Production
- North America: Dominated by companies like Merck and Sandoz, emphasizing strict GMP compliance and regulatory approvals.
- Europe: Suppliers such as Hikma and Sandoz provide certified APIs for regional and export markets.
- Asia: China represents a significant manufacturing hub with multiple API producers; capacity ranges from 2,000 to 8,000 kg annually.
Supply Chain Considerations
- Regulatory Acceptance: APIs from GMP-certified facilities in OECD countries have seamless approval pathways. Chinese API producers increasingly hold certifications recognized by regulatory agencies like the FDA and EMA.
- Quality & Purity: Suppliers must demonstrate batch-to-batch consistency, impurity profiles aligned with pharmacopoeias (USP, EP), and Good Manufacturing Practice (GMP) compliance.
- Pricing: Asia-based APIs often cost 20-30% less, but logistical and regulatory factors influence final costs.
- Supply Security: Reliance on a diversified supplier base reduces risk; however, geopolitical factors can impact supply stability.
Recent Trends and Developments
- Consolidation: Mergers such as Hikma acquiring BTG strengthen API manufacturing capacity.
- Regulatory Approvals: More Chinese API producers attain certifications to meet international standards.
- Capacity Expansion: Suppliers in China and Europe are expanding production to meet rising demand, partly driven by resistance to other antibiotics.
Key Players Summary
| Supplier |
Headquartered |
API Capacity (approx.) |
Certification Status |
Market Focus |
| Merck |
USA |
10,000 kg |
GMP, FDA-approved |
North America, Europe |
| Hikma / BTG |
UK |
2,500 kg |
GMP, CE |
Europe, Asia |
| Zhejiang Hisun |
China |
8,000 kg |
GMP, ISO |
Asia, Africa |
| Shanghai Rauheat |
China |
4,500 kg |
GMP |
Asia, Latin America |
| Sandoz |
Switzerland |
Custom |
GMP |
Global |
Note: Capacity figures are estimates derived from industry reports and supply chain disclosures.
Supply Chain Challenges
- Increased demand may strain existing capacity, causing price fluctuations.
- Regulatory hurdles differ regionally, impacting import/export cycles.
- Quality control variations among Chinese suppliers may influence selection and contractual risk assessments.
Key Takeaways
- The primary global API sources for daptomycin are located in North America, Europe, and China.
- Capacity ranges approximately from 2,500 to 10,000 kg/year across leading suppliers.
- API quality certification, especially GMP, influences supplier choice and market access.
- Chinese API manufacturers are expanding capacity and obtaining certifications but may pose logistical challenges.
- Diversification of providers minimizes supply disruptions amid geopolitical tensions.
FAQs
Q1: Which API manufacturers are approved by the FDA for daptomycin?
A1: Merck's US plants supply GMP APIs approved for the US market. Chinese manufacturers are increasingly gaining recognition but may require verification for specific markets.
Q2: Are Chinese API sources reliable for global supply?
A2: Many Chinese API producers hold GMP certificates and ISO standards. Supply stability depends on certification status, capacity, and quality control systems.
Q3: How does API capacity impact market prices?
A3: Higher capacity generally reduces prices due to economies of scale. Supply shortages can cause prices to surge, especially if capacity expansion is slow or restricted.
Q4: What are the common quality certifications for API suppliers?
A4: Good Manufacturing Practice (GMP), ISO 9001, and Certificate of Suitability (CEP) are standard certifications indicating compliance with quality standards relevant for pharmaceutical APIs.
Q5: How do geopolitical factors influence API sourcing?
A5: Tariffs, trade policies, and export restrictions in key regions like China and the US can affect API availability and pricing.
References
[1] U.S. Food and Drug Administration (FDA). (2022). API manufacturing facilities approval.
[2] European Medicines Agency (EMA). (2022). Certification and approval status of API suppliers.